Novel dual-mechanism anti-IgE antibody designed to improve upon existing and emerging therapies for IgE-mediated diseases Cue Biopharma plans to initiate global Phase 2b trial in food allergy followin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results